Paclitaxel-bevacizumab +/- atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial

Etude concernée: IFCT-2201
Auteurs / Authors: E. Giroux-Leprieur; A. Scherpereel; L. Greillier; V. Gounant; S. Hiret; L. Bigay-Game; G. Pavaut; M. Zysman; C. Deldycke; E. Berton; S. Galland-Girodet; C. Guguen; C. Mascaux; S. Couraud; O. Bylicki; M. El Hajjam; P. Fournel; A. Langlais; F. Morin; V. Westeel.
Journal / Conference: ESMO
Année / Year: 2025
PMID: Late breaking abstract
Lien vers la publication: https://clin.larvol.com/abstract-detail/ESMO%202025/77184584